Neurocrine Biosciences (NBIX), Intra-Cellular Therapies (ITCI), and Biohaven Pharmaceutical (BHVN) Are Top Potential Acquisition Targets for Biogen (BIIB) - Mizuho Investor Survey

January 31, 2022 2:25 PM EST
Get Alerts NBIX Hot Sheet
Price: $108.29 --0%

Rating Summary:
    19 Buy, 12 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 5 | Down: 13 | New: 15
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Mizuho analyst Salim Syed publishes final results from Mizuho's recent “Who Should Biogen (NASDAQ: BIIB) Buy?” investor survey.

122 investors responded to the survey. Here are 3 potential acquisition targets that received the most votes:

1. Neurocrine Biosciences (NASDAQ: NBIX) - 20 votes

2. Intra-Cellular Therapies (NASDAQ: ITCI) - 18 votes

3. Biohaven Pharmaceutical (NYSE: BHVN) - 17 votes

The survey was conducted following a recently announced agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis JV for an aggregate consideration of up to $2.3 billion.

It is speculated Biogen may use the freed up capital to pursue an acquisition.

BIIB closed at $225.21 yesterday.

Written by Vlad Schepkov | [email protected]

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Trader Talk

Related Entities

The Children's Investment Fund (TCI), Definitive Agreement, Vlad Schepkov